Skip to main content

Quest Diagnostics Inc(DGX-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Quest Diagnostics Granted FDA Breakthrough Designation for its Adeno-associated virus (AAV) Test

PR Newswire - Wed Aug 30, 2023

Quest and Sarepta Therapeutics Expand Collaboration to Develop AAV Companion Diagnostics (CDx) for Sarepta's Gene Therapies

SECAUCUS, N.J. and CAMBRIDGE, Mass., Aug. 30, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced that its AAVrh74 ELISA assay (CDx) has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). Breakthrough Device Designation is an FDA process designed to expedite the development and review of certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.